Becton, Dickinson and Company (NYSE: BDX) took a bit of a hit after earnings, from over $80 to under $78… Now the company’s BD Biosciences unit is out with new stem cell news. The company has announced the availability of its new BD Mosaic™ Mesenchymal Stem Cell Serum-Free (hMSC SF) offering. This is a complete cell culture environment for human mesenchymal stem cells derived from bone marrow. Think about stem cells for adults.
The cell culture environment is designed “to provide cell expansion in a shorter culture time—about half the time of traditional serum-based media. Starting with a low minimum seeding density (3,000–4,000 cells / cm2), BD Mosaic can achieve two or more doublings per passage without re-feeding between passages. Such performance can help deliver experimental results faster and lower total cost, as well as reduce handling and potential contamination.”
Today’s announcement shows that the performance provided by the cell culture environment can offer reliable results with speed and confidence. It noted, “The serum-free composition lessens variability and potential contamination events to further streamline the cell culture process and reduce risk.”
In conclusion, this is the first product in BD’s line of next-generation environments for the expansion of stem cells.
Keep in mind that Becton Dickinson has a market cap of $16.6 billion. This is a good area to go after, but it is going to take a lot to make a dent.
JON C. OGG
Top Gaining Stocks
Top Losing Stocks